The Anglo-Swedish drugmaker last month placed a $2 billion bet by licensing an experimental pill from China's Eccogene that it believes could cause fewer side effects than current injectable weight-loss treatments. AstraZeneca was "a few years behind" the runaway success of Novo and Lilly's drugs and was "working on the next wave of products", CEO Pascal Soriot told Reuters last month. The company is focusing on overweight population with risk factors like hypertension and kidney disease as opposed to a cosmetic market.
As VC Spectra Climbs, BNB and Polygon (MATIC) Feel the Pressure: The Crypto Community Takes Notice
oneindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oneindia.com Daily Mail and Mail on Sunday newspapers.
Inherent Biosciences, Inc Advances Fertility Solutions With Transformative Grant Funding From the NIH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Inherent Biosciences Inc: Inherent Biosciences, Inc Advances Fertility Solutions With Transformative Grant Funding From the NIH
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Inherent Biosciences, Inc Advances Fertility Solutions With Transformative Grant Funding From the NIH
torontotelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from torontotelegraph.com Daily Mail and Mail on Sunday newspapers.